Search

everythinglearnresearchcommunity

for

Search:↓

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

mrp/plf-mRNA can indicate tumor-promoting effects in skin.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Double-stranded RNA helps regenerate hair follicles by increasing retinoic acid production and signaling.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

17β-estradiol can reduce inflammation in the skin.

RNase L hinders hair follicle regeneration by altering immune signals.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

MARCKSL1 is important for wound healing and could be a target to reduce scarring.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

RNase L hinders hair growth by altering immune signals.

High amphiregulin in the skin is a bad sign for acute graft-versus-host disease.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Y27632 increases cell growth through EGFR signaling, not ROCK1/2.

Retinol may affect immune responses in people with frequent skin boils.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

RCS-01 cell therapy is safe and improves skin gene expression.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.